Valtensi Side Effects

Hypertension: Vascular and lymphatic system disorders: Decrease in the amount of hemoglobin and hematocrit, neutropenia, and thrombocytopenia.
Immune system disorders: Hypersensitivity and serum disorders.
Metabolic and nutritional disorders: Increase in serum potassium levels.
Hearing and labyrinth disorders: Vertigo.
Vascular disorders: Vasculitis.
Respiratory, thoracic and mediastinal disorders: Cough.
Indigestion: Abdominal pain.
Hepato-biliary disorders: Increase in liver action including increase in serum bilirubin.
Skin and subcutaneous tissue disorders: Angioedema, dermatitis bollus, rash and pruritus.
Musculoskeletal and connective tissue disorders: Myalgia.
Kidney and urinary disorders: Kidney disorders, increase in serum creatinine levels, increase in BUN level.
General disorders at the site of administration: Fatigue.
Other events have also been observed in patients with irrespective hypertension who have an association with valsartan: Arthralgia, asthenia, back pain, dizziness, headache, insomnia, decreased libido, nausea, edema, pharyngitis, rhinitis, sinusitis, upper respiratory tract infections, viral infections.
Post myocardial infarction and/or heart failure: Side effects that may occur in patients after myocardial infarction and/or heart failure are:
Vascular and lymphatic system disorders: Thrombocytopenia.
Immune system disorders: Hypersensitivity and serum disorders.
Metabolic and nutritional disorders: Hypercalcemia; unknown: increased serum potassium levels.
Hearing and labyrinth disorders: Vertigo.
Heart disorders: Heart failure.
Vascular disorders: Hypotension, orthostatic hypotension; unknown: vasculitis.
Respiratory, thoracic and mediastinal disorders: Cough.
Indigestion: Nausea, diarrhea.
Hepato-biliary disorders: Increased liver action.
Skin and subcutaneous tissue disorders: Angioedema; unknown: rash and pruritus.
Musculoskeletal and connective tissue disorders: Myalgia.
Kidney and urinary disorders: Renal failure; acute renal impairment, elevated creatinine levels; increased levels of BUN.
General disorders at the site of administration: Asthenia and fatigue.
Other disorders observed in patients with post-myocardial infarction and/or heart failure are not related to drug studies: Arthralgia, abdominal pain, back pain, insomnia, decreased libido, neutropenia, edema, pharyngitis, rhinitis, sinusitis, upper respiratory infections and viruses.